Pulse Biosciences, Inc.
PLSE
$25.55
$1.184.84%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 401.00K | 264.00K | 86.00K | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 401.00K | 264.00K | 86.00K | -- | -- |
| Cost of Revenue | 370.00K | 260.00K | 279.00K | -- | -- |
| Gross Profit | 31.00K | 4.00K | -193.00K | -- | -- |
| SG&A Expenses | 6.59M | 7.33M | 8.78M | 8.19M | 7.73M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 19.55M | 18.52M | 20.45M | 20.28M | 18.04M |
| Operating Income | -19.15M | -18.25M | -20.37M | -20.28M | -18.04M |
| Income Before Tax | -18.58M | -17.43M | -19.39M | -19.17M | -16.80M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -18.58M | -17.43M | -19.39M | -19.17M | -16.80M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -18.58M | -17.43M | -19.39M | -19.17M | -16.80M |
| EBIT | -19.15M | -18.25M | -20.37M | -20.28M | -18.04M |
| EBITDA | -18.90M | -17.99M | -20.11M | -20.00M | -17.76M |
| EPS Basic | -0.27 | -0.26 | -0.29 | -0.28 | -0.25 |
| Normalized Basic EPS | -0.17 | -0.16 | -0.18 | -0.18 | -0.16 |
| EPS Diluted | -0.27 | -0.26 | -0.29 | -0.28 | -0.25 |
| Normalized Diluted EPS | -0.17 | -0.16 | -0.18 | -0.18 | -0.16 |
| Average Basic Shares Outstanding | 67.99M | 67.79M | 67.39M | 67.28M | 67.13M |
| Average Diluted Shares Outstanding | 67.99M | 67.79M | 67.39M | 67.28M | 67.13M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |